Mirna Therapeutics Inc (MIRN) was Downgraded by Leerink Partners to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Leerink Partners advised their investors in a research report released on Aug 16, 2016.
Mirna Therapeutics Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy microRNA Replacement Therapy focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. Its pipeline of products includes MRX34 miR-101 miR-215 let-7 and miR-16. The Company’s lead product candidate MRX34 a mimic of naturally occurring microRNA-34 (miR-34) is in Phase I clinical trial in patients with primary liver cancer advanced solid tumors and hematological malignancies. Its miR-34 is considered a key regulator of multiple oncogenes across key oncogenic pathways. The Company focuses on developing MRX34 as a monotherapy and in combination with other therapeutic modalities such as targeted therapies and immuno-oncology agents.